Progress in Prophylaxis against nonsteroidal anti-inflammatory drug- associated ulcers and erosions

American Journal of Medicine

Volumn 104, Issue 3 A, 1998, Pages

  Hawkey, Christopher J ^a,b  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROSTAGLANDIN E1 DERIVATIVE; PROTON PUMP INHIBITOR; RANITIDINE;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG TOLERANCE; DUODENUM ULCER; DYSPEPSIA; FEMALE; GRAM NEGATIVE INFECTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOARTHRITIS; PEPTIC ULCER; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; RHEUMATOID ARTHRITIS; STOMACH EROSION; TREATMENT FAILURE; ULCER HEALING;

EID: 0032579893     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00215-5     Document Type: Conference Paper

References (26)

1. Ekström P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy - a Nordic multicentre study. Scand J Gastroenterol. 1996;31:753-758.
2. Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for NSAID users. Gastroenterology. 1996;110:A86.
3. Hawkey CJ, Karrasch JA, Szczepánski L, et al. A comparison of omeprazole and misoprostol for treating and preventing ulcers associated with nonsteroidal anti-inflammatory drugs: the OMNIUM study. N Engl J Med. 1998; (in press).
4. Yeomans ND, Tulassay Z, Juhász L, et al. Comparison of omeprazole and ranitidine for treating and preventing ulcers associated with nonsteroidal anti-inflammatory drugs: the ASTRONAUT study. N Engl J Med. 1998; (in press).
5. Cullen DJE for the Nottingham 2000 Intervention Group. Suitability of ibuprofen for widespread ulcer-sparing use in the community. Gastroenterology. 1994;106:A6.
6. Paakkari I. Epidemiological and financial aspects of the use of non-steroidal anti-inflammatory analgesics. Pharmacol Toxicol. 1994;75(suppl II):56-59.
7. Hawkey CJ. Nonsteroidal anti-inflammatory drugs and ulcers: facts and figures multiply, but do they add up? BMJ. 1990;300:278-284.
8. Henry D, Robertson J. Non-steroidal anti-inflammatory drugs and peptic ulcer hospitalisation rates in New South Wales. Gastroenterology. 1993;104:1083-1091.
9. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomised, double-blind, placebo controlled trial. Ann Intern Med. 1995;123:241-249.
10. Lanza FL, Aspinall RL, Swabb EA, et al. Double-blind placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. Gastroenterology. 1988;95:289-294.
11. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet. 1988;2:1277-1280.
12. Hawkey CJ, Cullen D. Arthrotec for all? (Editorial.) Ann Rheum Dis. 1993;52:841-842.
13. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med. 1995;123:344-350.
14. Ehsannullah RS, Page MC, Tidesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ. 1988;297:1017-1021.
15. Robinson MG, Griffin JW Jr, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig Dis Sci. 1989;34:424-428.
16. Daneshmend TK, Prichard PJ, Bhaskar NK, et al. Use of microbleeding and an ultrathin endoscope to assess gastric mucosal protection by famotidine. Gastroenterology. 1989;97:944-949.
17. Daneshmend TK, Stein AG, Bhaskar NK, Hawkey CJ. Abolition by omeprazole of aspirin induced gastric mucosal injury in man. Gut. 1990;31:514-517.
18. Bigard MA, Isal JP. Prevention of aspirin-induced gastric lesions by omeprazole in healthy subjects. Gastroenterology. 1989;96:A44.
19. Scheiman JM, Behler EM, Loeffler KM, Elta GH. Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci. 1994;39:97-103.
20. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by non steroidal antiinflammatory drugs. N Engl J Med. 1996;334: 1435-1439.
21. Yeomans ND for the Omeprazole NSAID Steering Committee. New data on healing of NSAID-associated ulcers and erosions. Am J Med. 1998;104(3A):56S-61S.
22. 4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut. 1993;34:742-747.
23. Gabriel SE, Jaakkimainen L, Bombardier C. Risks for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787-796.
24. Hudson N, Taha AS, Russell RI, et al. High-dose famotidine as healing and maintenance treatment for non-steroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology. 1997;112:1817-1822.
25. Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology. 1996;110: 725-732.
26. NIH Consensus Development Panel. Helicobacter pylori in peptic ulcer disease. JAMA. 1994;272:65-69.